United States: Federal Circuit Invalidates Prandin Patent Claim As Obvious

In its third look at the Novo Nordisk A/S patent related to Prandin®, in Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories Ltd., the Federal Circuit affirmed the district court's finding that claim 4 of U.S. Patent No. 6,677,358 is invalid as obvious, but reversed the district court's finding that the patent is unenforceable due to inequitable conduct. This decision illustrates both the difficulty of sustaining a patent based on unexpected results and the difficulty of invalidating a patent based on inequitable conduct.

The Patent at Issue

The patent at issue in this case is U.S. Patent No. 6,677,358, which is listed in the FDA's Orange Book for Novo Nordisk's Prandin® repaglinide product. Claim 4 recites a "method for treating non-insulin dependent diabetes mellitus (NIDDM) comprising administering to a patient in need of such treatment repaglinide in combination with metformin."

As summarized by the Federal Circuit, "Type II diabetes can be treated with orally administered antidiabetic drugs ("OADs") in the form of monotherapy (a single OAD) or combination therapy (more than one OAD)." The drug repaglinide is an insulin secretagogue that works by stimulating insulin release from pancreatic beta cells, while the drug metformin is an insulin sensitizer that reduces insulin resistance by acting on the liver to reduce glucose production and thereby improve insulin sensitivity in muscle and fat tissues. The patent at issue arose from Novo Nordisk's discovery that combination therapy with both repaglinide and metformin achieved better results than monotherapy with either drug.

The District Court Decision

Caraco filed an Abbreviated New Drug Application in 2005, seeking FDA approval to market a generic version of Prandin®. Caraco's ANDA included a Paragraph IV certification asserting that the '358 patent was invalid or would not be infringed by its product. In response, Novo Nordisk brought suit under the Hatch-Waxman patent litigation framework, asserting claim 4 of the '358 patent. Caraco filed a counterclaim asserting invalidity and unenforceability. The district court conducted a bench trial, and held claim 4 invalid as obvious and that the patent was not enforceable because of inequitable conduct. Novo Nordisk appealed.


The parties did not dispute the district court's finding that Caraco had presented a prima facie case that "it was obvious to try combination therapy using metformin and repaglinide to treat Type II diabetes." In particular, "[i]t was apparently well-known in the art that two drugs having different mechanisms for attacking diabetes may be more effective than one, and so drugs were often tested in combination therapy after demonstrating effectiveness in monotherapy." Moreover, "[c]ombination therapy using insulin sensitizers and insulin secretagogues was common at the time, and metformin was the most widely-used insulin sensitizer as of the '358 patent's filing date." Thus, the issue before the court was whether the combination therapy achieved surprising and unexpected results, such as "synergistic" results." The district court found that it did not.

On appeal, Novo Nordisk lodged three main challenges to the district court decision, but the Federal Circuit was not persuaded by any of them.

First, Novo Nordisk asserted that "the district court misallocated the burden of persuasion in this case by forcing Novo to 'overcome' Caraco's 'prima facie' case of obviousness with evidence of unexpected results."

However, the Federal Circuit found that the district court properly had applied the presumption of validity by requiring Caraco to come forward with evidence of invalidity in the first instance. Only after finding "that Caraco's prima facie evidence, if unrebutted, would be sufficient to establish that the repaglinide/metformin combination was obvious to try, and that a person of ordinary skill in the art would have reasonably expected the combination would yield success in the form of beneficial, and even synergistic, results" did the district court "consider whether Novo's countervailing secondary consideration evidence of unexpected synergy (i.e., its "attempt to prove unexpected results") was sufficient to 'overcome' Caraco's prima facie case. Further, after evaluating "all evidence of unexpected synergy and commercial success," the district court "concluded that ... Caraco had shown by clear and convincing evidence that the combination was obvious."

Second, Novo argued that "even if the burdens were properly allocated in this case, Caraco's evidence insufficiently supported the court's ultimate obviousness findings."

The Federal Circuit disagreed. Novo Nordisk's position was based on unexpected results vis-ŕ-vis "repaglinide's known efficacy in monotherapy." In contrast, the district court's analysis followed a three-step reasoning:
(1) the closest prior art [to the repaglinide/metformin combination] was combination therapy using metformin and a sulfonylurea;
(2) combination therapy using metformin and one of the sulfonylurea class of secretagogues was well known in the art to produce beneficial and even synergistic results in controlling glucose levels in Type II diabetes patients; [and]
(3) repaglinide was known as an insulin secretagogue having a similar mechanism of action to the sulfonylurea class of secretagogues.
The Federal Circuit found no error in the district court's analysis:

It is reasonable that an artisan seeking to combine a known insulin sensitizer (like metformin) with a new insulin secretagogue (like repaglinide) would base his expectations upon prior art sensitizer/secretagogue combinations.

Third, Novo urged that "the district court should have deferred to the examiner's original finding that the Sturis and Moses studies demonstrated unexpected synergy."

This argument was based on the recent Supreme Court decision in Kappos v. Hyatt, which the Federal Circuit found "has no relevance here." As explained by the court, "the initial determinations by the PTO in determining to grant the application are entitled to no deference as they would be in an appeal to this court under 28 U.S.C. § 1295(4)(A) or (absent new evidence) in a district court proceeding under 35 U.S.C. § 145. Rather, we treat the issued patent as having a presumption of validity that must be overcome by clear and convincing evidence. No decision of the Supreme Court or this court has ever suggested that there is an added burden to overcome PTO findings in district court infringement proceedings. ... Neither are we persuaded that the presence or absence of PTO findings on particular issues affects the basic presumption of validity."

Having rejected Novo Nordisk's challenges to the district court decision, the Federal Circuit affirmed the district court's finding of obviousness.

Inequitable Conduct

Caraco's inequitable conduct charges stemmed from statements and omissions in two expert declarations that had been submitted to the USPTO during prosecution of the '358 patent as evidence of unexpected results and the synergistic effect of the combination therapy. The district court found that the statements and omissions were "but for" material under the Federal Circuit's en banc decision in Therasense because the USPTO examiner had relied upon the declarations when deciding to withdraw the obviousness rejections. The Federal Circuit disagreed.

Although the court found that some of the statements and omissions at issue were "troubling," it could "not see how [the] omissions qualify as 'but for' material." The court emphasized:

This is not a case where a declarant hid adverse test results from the PTO in favor of more promising data selected post hoc. ... Nor is this a case where the declarant's omission expressly undermined his stated opinion. To the contrary, even after taking the omitted test protocol into account, the court specifically found that Dr. Sturis's conclusions on synergy had not been shown to be false.

Having found that the materiality prong of the inequitable conduct test was not satisfied, the Federal Circuit reversed the finding of inequitable conduct.

Speaking of Therasense, is the USPTO ever going to revise its guidance on the Duty of Disclosure to take this case into consideration?

The Back Story

Please see this article for a discussion of the Supreme Court decision which held that 21 USC § 355(j)(5)(C)(ii)(I) provided Caraco with a mechanism for challenging the use code that Novo Nordisk had provided in its Orange Book listing for Prandin®.

Please see this article for a discussion of the Federal Circuit decision which revised the district court's injunction requiring Novo Nordisk to replace the original use code with specific language.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.